Gene Silencing Genetics Hormones 
pharmaphorum
JULY 28, 2022
Alnylam Pharma has made a name for itself, developing gene-silencing therapies for rare disorders, but its latest discovery could take it into a much larger category – metabolic and cardiovascular disease.
pharmaphorum
DECEMBER 23, 2020
NT-814 is a non-hormonal drug that works on the neurokinin (NK) 1,3 receptor antagonist, thus treating the vasomotor symptoms associated with the menopause. The company’s menopause drug NT-814 is heading for phase 3 development in 2021 following a mid-stage trial readout.
Delveinsight
AUGUST 6, 2020
Transthyretin (TTR) is a protein that the liver produces to facilitate the transfer of thyroid hormone and vitamin A in the blood. The hATTR diagnosis is mainly dependent on symptoms and can be confirmed via performing tissue biopsies, genetic testing, and imaging studies. Gene-silencing Therapies.
Expert insights. Personalized for you.
52 
Let's personalize your content